📊 SCLXW Key Takeaways
Is Scilex Holding Co (SCLXW) a Good Investment?
Scilex is technically insolvent with -$207.8M negative stockholders equity and faces an acute liquidity crisis with a 0.08x current ratio unable to cover obligations. Revenue collapsed 46.5% YoY while operating losses exceed -1143% margin, indicating severe business deterioration despite marginal improvement in net loss magnitude and positive operating cash flow.
Why Buy Scilex Holding Co Stock? SCLXW Key Strengths
- Operating cash flow remains positive at $3.8M despite enormous accounting losses, suggesting underlying cash generation despite reported losses
- Net loss improved 7.1% YoY, indicating losses are decelerating from worse prior year levels
- Long-term debt is zero, avoiding additional servicing burden
SCLXW Stock Risks: Scilex Holding Co Investment Risks
- Negative stockholders equity of -$207.8M indicates technical insolvency; liabilities ($576.7M) far exceed assets ($365.0M)
- Critical liquidity crisis with current ratio of 0.08x and only $5.0M cash reserves; unable to cover short-term obligations
- Severe revenue collapse of -46.5% YoY combined with operating margin of -1143.7% indicates fundamental business failure; suspicious 415.8% gross margin suggests accounting irregularities
- No insider buying activity in past 90 days while company faces distress
Key Metrics to Watch
- Stockholders equity trend and path to positive book value
- Operating cash flow sustainability and monthly cash burn rate
- Revenue stabilization and return to growth
Scilex Holding Co (SCLXW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SCLXW Profit Margin, ROE & Profitability Analysis
SCLXW vs Healthcare Sector: How Scilex Holding Co Compares
How Scilex Holding Co compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Scilex Holding Co Stock Overvalued? SCLXW Valuation Analysis 2026
Based on fundamental analysis, Scilex Holding Co has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Scilex Holding Co Balance Sheet: SCLXW Debt, Cash & Liquidity
SCLXW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Scilex Holding Co's revenue has grown significantly by 49% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.05 indicates the company is currently unprofitable.
SCLXW Revenue Growth, EPS Growth & YoY Performance
SCLXW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.6M | -$4.4M | $-0.58 |
| Q2 2025 | $9.9M | -$24.4M | $-7.42 |
| Q1 2025 | $5.0M | -$24.4M | $-2.26 |
| Q3 2024 | $10.1M | -$4.4M | $-0.03 |
| Q2 2024 | $12.6M | -$26.6M | $-0.19 |
| Q1 2024 | $10.6M | -$24.4M | $-0.22 |
| Q3 2023 | $10.1M | -$5.5M | $-0.04 |
| Q2 2023 | $7.9M | -$17.8M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Scilex Holding Co Dividends, Buybacks & Capital Allocation
SCLXW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Scilex Holding Co (CIK: 0001820190)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SCLXW
What is the AI rating for SCLXW?
Scilex Holding Co (SCLXW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SCLXW's key strengths?
Claude: Operating cash flow remains positive at $3.8M despite enormous accounting losses, suggesting underlying cash generation despite reported losses. Net loss improved 7.1% YoY, indicating losses are decelerating from worse prior year levels.
What are the risks of investing in SCLXW?
Claude: Negative stockholders equity of -$207.8M indicates technical insolvency; liabilities ($576.7M) far exceed assets ($365.0M). Critical liquidity crisis with current ratio of 0.08x and only $5.0M cash reserves; unable to cover short-term obligations.
What is SCLXW's revenue and growth?
Scilex Holding Co reported revenue of $30.3M.
Does SCLXW pay dividends?
Scilex Holding Co pays dividends, with $8.7M distributed to shareholders in the trailing twelve months.
Where can I find SCLXW SEC filings?
Official SEC filings for Scilex Holding Co (CIK: 0001820190) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SCLXW's EPS?
Scilex Holding Co has a diluted EPS of $-36.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SCLXW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Scilex Holding Co has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SCLXW stock overvalued or undervalued?
Valuation metrics for SCLXW: ROE of N/A (sector avg: 15%), net margin of -1,236.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SCLXW stock in 2026?
Our dual AI analysis gives Scilex Holding Co a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SCLXW's free cash flow?
Scilex Holding Co's operating cash flow is $3.8M, with capital expenditures of $133.0K. FCF margin is 12.2%.
How does SCLXW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,236.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.08 (avg: 2).